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Understanding how drugs work in vivo is critical for
drug design and for maximizing the potential of
currently available drugs. 5-nitrofurans are a class
of prodrugs widely used to treat bacterial and
trypanosome infections, but despite relative speci-
ficity, 5-nitrofurans often cause serious toxic side
effects in people. Here, we use yeast and zebrafish,
as well as human in vitro systems, to assess the
biological activity of 5-nitrofurans, and we identify
a conserved interaction between aldehyde dehydro-
genase (ALDH) 2 and 5-nitrofurans across these
species. In addition, we show that the activity of
nifurtimox, a 5-nitrofuran anti-trypanosome prodrug,
is dependent on zebrafish Aldh2 and is a substrate
for human ALDH2. This study reveals a conserved
and biologically relevant ALDH2-5-nitrofuran interac-
tion that may have important implications for
managing the toxicity of 5-nitrofuran treatment.
INTRODUCTION
Drugs often have multiple targets in vivo that can lead to unin-
tended side effects. Identifying unintended drug targets and their
in vivo relevance is a fundamental challenge in chemical biology.
5-Nitrofurans are a class of drugs that save thousands of lives as
front-line treatments for parasitic trypanosome infections in Latin
America and Africa, and they are also effective antibiotics in
human and veterinary medicine (Castro et al., 2006; Coura and
Vin˜as, 2010; Nussbaum et al., 2010; Priotto et al., 2009). 5-Nitro-
furans are of such importance to human health that the World
HeathOrganization deems the 5-nitrofuran, nifurtimox, an essen-Chemistry & Biology 19,tial medicine and Bayer HealthCare provides nifurtimox free of
charge for trypanosome infections. 5-Nitrofurans are prodrugs,
and their relative specificity comes from parasitic and bacteria-
specific nitroreductases (NTRs) that reduce the 5-NO2 functional
group to a toxic anion radical, therebygenerating reactiveoxygen
species and inducing cell death. Despite their widespread use,
5-nitrofurans have serious toxic side effects (Castro et al.,
2006). For nifurtimox, toxic side effects lead to treatment cessa-
tion in over 30%ofpatientswithChagasdisease,which is caused
by Trypanosoma cruzi infection (Castro et al., 2006). Clinical side
effects are complex and can vary between populations, but they
include polyneuropathy, depression, forgetfulness, alcohol intol-
erance, and headaches, as well as gastrointestinal complica-
tions. There is currently no treatment strategy available to reduce
the off-target toxic side effects of 5-nitrofurans.
Over decades of research, scientists have identified multiple
human enzymes capable of 5-nitrofuran reduction in vitro, in
cells or tissues (Dubuisson et al., 2001; Rao et al., 1987; Rao
and Mason, 1987). However, the question of whether these
enzymes are relevant to 5-nitrofuran side-effect activity and
the potential for therapeutic intervention to inhibit their off-target
activity in vivo is unanswered. Drug mechanism of action is
readily examined in the zebrafish model system, in which clini-
cally active compounds can be directly assayed in the trans-
parent embryo (Zon and Peterson, 2005). Within 2 to 5 days of
development in zebrafish, most tissues and organs have formed,
thereby enabling the identification of tissue-specific drug activi-
ties and/or bioactivation. These features allow facile phenotypic
chemical screens within the whole animal. Phenotypic small-
molecule screens in zebrafish have enabled the identification
of new biological pathways, novel bioactive chemicals, and
unexpected potential for known drugs (Taylor et al., 2010). Drugs
often have multiple targets in vivo, and examining the effects of
small molecules on the developing zebrafish can also identify
unintended drug targets (Ishizaki et al., 2010; Ito et al., 2010;
Laggner et al., 2012; Rihel et al., 2010).883–892, July 27 , 2012 ª2012 Elsevier Ltd All rights reserved 883
Figure 1. 5-Nitrofurans Promote Melanocytotoxicity in Zebrafish
(A and B) Examples of zebrafish embryos treated at 2 dpf for 48 hr with DMSO as a control, plus 5 mM NFN1 and 5 mM NFN1.1 (A) or 50 mM nifurtimox (B). Black
melanocytes (red arrows) and melanocyte detritus (blue arrows) are indicated.
(C) Chemical structures of the four 5-nitrofurans (NFN1–4 [Maybridge compounds BTB05727, SEW00138, BTB13657, and BR00087]) identified in a chemical
screen for modulators of melanocyte development. The 5-NO2-furan functional group shared between the 5-nitrofurans, including nifurtimox, is indicated in red.
The chemical structure of NFN1.1. is identical to that of NFN1 but lacks the 5-NO2 functional group required for activity (blue).
See also Figure S1 and Movie S1.
Table 1. Derivatives of 5-Nitrofurans and Their Activity in
Zebrafish
Compound 0.2 mM 0.4 mM 0.8 mM 1.6 mM
NFN1 No activity No activity + +++
NFN1.1 No activity No activity No activity No activity
NFN5 No activity + ++ ++++
NFN5.1 No activity + ++ ++
NFN5.2 No activity + ++ ++++a
+Some melanocytes become dendritic, few are fragmented.
++Some punctate and fragmented melanocytes.
+++All melanocytes are punctate, many clearly fragmented, pigment
remains in eye.
++++All melanocytes are fragmented, with almost complete loss of
pigment in body and eye.
aAdditional nonspecific toxicity.
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ALDH2 Mediates 5-Nitrofuran ActivityHere, we use a multispecies approach to identify ALDH2 as
a mediator of 5-nitrofuran toxicity in yeast and zebrafish, and
we show that 5-nitrofurans are substrates for human ALDH2
in vitro. In a zebrafish phenotypic screen, we found that 5-nitro-
furans are melanocytotoxic. We exploited this highly visible
in vivo activity to generate a 5-nitrofuran probe, identify ALDH2
as a 5-nitrofuran target, and validate the interaction in vivo.
This interaction is conserved from yeast to human, and is also
relevant for the clinically active 5-nitrofuran nifurtimox. We
propose that this new interaction may be relevant to some of
the 5-nitrofuran toxicity observed in the clinic.
RESULTS
5-Nitrofurans Are Active in Zebrafish
Melanocytes are pigment-producing cells that generate black
melanin, and pigmented melanocytes are clearly visible in the
developing zebrafish beginning at 28 hr postfertilization (hpf;
Figure 1A). We identified four 5-nitrofuran compounds, NFN1
(Maybridge BTB05727), NFN2 (SEW00138), NFN3 (BTB13657),
and NFN4 (BR00087), in a chemical screen for modulators of
melanocyte development in zebrafish embryos (Figures 1A and
1C; see Methods). We also found that zebrafish were sensitive
to the clinically active 5-nitrofuran nifurtimox (Figures 1B and
1C). 5-Nitrofuran treatment directly affected the melanocyte
andmelanocyte progenitor viability in a dose-dependent manner
and was independent of tyrosinase activity (Figure S1 available
online; Movie S1). Thus, 5-nitrofurans are melanocytotoxic in
zebrafish, and unlike prodrugs that are bioactivated by pigmen-
tation enzymes (Jawaid et al., 2009; Yang and Johnson, 2006),
their activity is independent of tyrosinase. Altered pigmentation
is not a feature of 5-nitrofuran toxicity in humans, but melanocyte
specificity in zebrafish provided a rapid, convenient, and highly884 Chemistry & Biology 19, 883–892, July 27 , 2012 ª2012 Elseviervisible assay to study 5-nitrofuran activity in an animal model,
independent of trypanosome infection.
5-Nitrofuran Activity Requires the 5-NO2 Moiety
5-Nitrofurans are prodrugs, and the 5-NO2moiety is essential for
bioactivation in parasites and bacteria (Maya et al., 2007). We
modified NFN1 by replacing the NO2 moiety with a hydrogen
atom (Figure 1C, NFN1.1; Table 1; Supplemental Information).
In contrast to treatment with NFN1, NFN1.1 had no effect on
zebrafish melanocytes, and the melanocyte remained pig-
mented and intact (Figure 1A; Table 1). Nitrofuran activity in
melanocytes is therefore dependent upon the 5-NO2 functional
group. As in humans, zebrafish do not have NTRs (which are
present in trypanosomes) to process the 5-NO2 functional group,
and thus, the effects of NFN1 on zebrafish melanocytes mayLtd All rights reserved
Figure 2. 5-Nitrofurans Bind Aldh2 in Zebrafish
(A) Biotinylated probes linked to a 5-nitrofuran (Pr-NFN)
and a control furan (Pr-FN). Biotin is labeled in blue and the
5-nitro or modification moiety in red.
(B) Silver stain of protein bands identified using Pr-NFN
probe, or streptavidin beads alone as a control (No Probe).
The red box indicates the region of the gel that was iso-
lated for mass spectrometry analysis (arrow) at 57 kD.
(C) Western blot of zebrafish protein bound to the no-
probe control, the furan (Pr-FN) control, or the 5-nitrofuran
probe (Pr-NFN), and probed with zebrafish anti-Aldh2
antibodies. A band corresponding to 57 kDa is indicated
(arrow). MW, molecular weight.
See also Figure S2 and Table S1.
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processing.
Nitrofurans Bind ALDH2 in Zebrafish
To identify the possible targets of the 5-nitrofurans, we per-
formed affinity purification to capture 5-nitrofuran interacting
proteins in zebrafish extracts. First, we generated a series of
5-nitrofuran derivatives and tested their activity in zebrafish
(Table 1; Supplemental Information). Importantly, 5-nitrofuran
derivatives containing a phenyl ring (NFN5, NFN5.1, NFN5.2)
effectively targeted zebrafishmelanocytes (Table 1). As substitu-
tion at the para position of the phenyl ring in NFN5.1 and NFN5.2
was tolerated, a 5-nitrofuran probe was generated by linking
to biotin through the para position of the phenyl ring (Pr-NFN;
Figure 2A). Next, the 5-nitrofuran probe was bound to streptavi-
din beads, and protein complexes captured from zebrafish
extract derived from 3-day embryos were subjected to tandem
mass spectrometry. A 57-kD binding protein was identified
as aldehyde dehydrogenase (Aldh) 2b (Figure 2B; Table S1).
Zebrafish have two aldh2 (Lassen et al., 2005; Song et al.,
2006) genes (a and b) that are orthologs of human ALDH2 (Fig-
ure S2); aldh2b is expressed in neural crest derived cells,
including presumptive melanocytes (Thisse et al., 2001). To
confirm the identity of the 57-kD protein, we repeated our affinity
purification protocol and performed western blotting with anti-
Aldh2 zebrafish antibodies raised against both a and b forms
of Aldh2 (Lassen et al., 2005) (Figure 2C). As a control, we gener-
ated a furan probe that was identical to the nitrofuran probe
except that it lacked the 5-NO2 functional group (Pr-FN; Fig-
ure 2A). Aldh2 (either a or b) bound more strongly to the 5-nitro-
furan probe than to the control probe, and not to streptavidin
beads alone (Figure 2C). These experiments validate Aldh2 as
a 5-nitrofuran binding protein.
Aldh2 Is Required for 5-Nitrofuran Activity in Zebrafish
Aldh2 catabolizes toxic aldehydes in the liver after alcohol
consumption (Druesne-Pecollo et al., 2009), in the heart after
ischemia (Chen et al., 2008), and in dopamine metabolism (Yao
et al., 2010). We asked if 5-nitrofuran toxicity was dependent
on Aldh2 in zebrafish. The natural product daidzin, found in the
Kudzu vine (Pueraria lobata), is a potent and specific inhibitor
of human ALDH2 and has long been used in traditional medi-
cines as an antidipsotropic (Keung and Vallee, 1993a, 1993b;
Lowe et al., 2008). More recently, ALDH2 inhibitors have beenChemistry & Biology 19,shown to reduce anxiety associated with treatment of cocaine
and alcohol addiction (Arolfo et al., 2009; Yao et al., 2010). We
reasoned that ALDH2 inhibitors were likely to prevent the toxicity
of 5-nitrofurans in zebrafish because (1) human ALDH2 is closely
related to zebrafish Aldh2 (a and b forms) (Figure S2), and (2)
computational modeling of zebrafish Aldh2b bound to daidzin
suggests that critical drug-protein interactions are conserved
between species (Figure 3A). Treatment of zebrafish embryos
with daidzin protected melanocytes from the cytotoxicity of the
coadministered 5-nitrofuran NFN1 (Figure 3B), as well as the
clinically active 5-nitrofuran nifurtimox (Figure 3C). Thus, coad-
ministration of the Aldh2 inhibitor daidzin abrogates the activity
of NFN1 and nifurtimox in zebrafish.
To provide additional evidence that the action of daidzin was
by inhibition of Aldh2 and not an additional unintended target,
zebrafish embryos were cotreated with NFN1 and a second
ALDH1/2 inhibitor, disulfiram (DSF). DSF, also called Antabuse
and Antabus, is used to treat chronic alcoholism by preventing
the ALDH2-dependent metabolism of alcohol and producing
enhanced sensitivity to alcohol. DSF also chelates copper, and
we and others have found that DSF prevents pigmentation of
zebrafish melanocytes prior to melaninization, most likely due
to inhibition of copper-dependent pigmentation enzymes (Fig-
ure S3; O’Reilly-Pol and Johnson, 2008). DSF treatment of
embryos 3 days postfertilization (dpf) that had fully pigmented
melanocytes had no effect on melanocyte integrity, while DSF
prevented melanocyte toxicity upon cotreatment with NFN1
(Figure 3B). Taken together, these experiments with two chemi-
cally independent ALDH2 inhibitors support a biological role for
Aldh2 in the bioactivation of 5-nitrofuran melanocytotoxicity in
zebrafish.
ALDH2 is regulated in a tissue-specific manner, and in partic-
ular, εPKC can directly modulate ALDH2 during ischemic pre-
conditioning in the heart (Chen et al., 2008, 2010). We identified
the PKC inhibitors PKC412 and Ro318220 as chemical suppres-
sors of 5-nitrofuran activity in zebrafish by screening a library
of 80 known kinase inhibitors. Treatment of 3 dpf zebrafish
embryoswith PKC412 or Ro318220 had no effect onmelanocyte
viability (Figure 3B). However, treatment with PKC412 or
Ro318220 prevented NFN1 activity in melanocytes (Figure 3B).
We tested a third PKC inhibitor, GF109203X, that can inhibit
ethanol or dopamine D2 receptor agonist NPA-induced intracel-
lular translocation of εPKC (Yao et al., 2008). GFX109203X had
no effect on melanocytes alone, but we found that it could also883–892, July 27 , 2012 ª2012 Elsevier Ltd All rights reserved 885
Figure 3. Aldh2 Is Responsible for 5-Nitrofuran Activity in Zebrafish
(A) A predicted model of daidzin binding to zebrafish ALDH2b, based on key residues involved in the human ALDH2-daidzin (PDB 2vle) protein-ligand interaction
(Lowe et al., 2008). The equivalent residues in zebrafish Aldh2b are shown. Human ALDH2/Zebrafish Aldh2 2b (Phe-459/Phe-457; Phe-170/Phe-186;
Trp-177/Trp-193; Val-120/Val-136; Phe-296/Phe-312; Phe-292/Ile-308; Asp-457/Asn-473; Cys-303/Cys-319).
(B) Aldh2 and PKC inhibitors prevent 5-nitrofuran activity in zebrafish. Examples of zebrafish embryos treated at 2 dpf with 20 mM of the ALDH inhibitors daidzin
or DSF for 1 hr, or with 20 mM of the PKC inhibitors PKC412 or Ro318220, and then treated with 5 mM NFN1 or 0.1% DMSO alone for 2 days. Experiments were
repeated at least three times, with n > 10 embryos per condition.
(C) Examples of 2 dpf zebrafish embryos pretreated with DMSO, 30 mM of daidzin, or the PKC inhibitor GFX 109203X for 1 hr, and then treated with 50 mM
nifurtimox for 7 hr. Punctatemelanocytes are indicated. Experiments were repeated at least three times (n = 5–10 embryos per condition) and treatment-condition
cohorts blind scored.
(D) Daidzin alters background adaptation in zebrafish embryos. (Left) Images of fixed zebrafish embryos (5 dpf) treated with 0.1% DMSO or 10 mM daidzin, and
shifted from a dark environment to a light environment (light), or vice versa (dark). The average percentage of melanin coverage (within the area indicated by the
red dotted outline) for each treatment condition ± SD is indicated. (Right) Box plot of melanin coverage (y axis) for each embryo in different treatment conditions
(x axis). Individual values taken from one of three experiments are shown as red circles. The box depicts the lower quartile and the upper quartile, with the median
depicted by the intersecting line. Whiskers extend between the minimum and maximum of all the data. In DMSO-treated embryos, melanocytes are significantly
contracted in the light and expanded in the dark (p < 0.001, n = 20 for each condition; ANOVA, 95% confidence interval [CI] 11.081[5.966, 16.195]). Zebrafish
treatedwith daidzin contract their melanin in response to light environment but do not significantly expand their melanin in response to dark environments (95%CI
0.563[4.552, 5.677]). The experiment was repeated three separate times with embryos at 5 dpf (n = 5–20 embryos per condition) and once with embryos at 4 dpf
(n = 10 embryos per condition).
See also Figure S3.
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was also effective at preventing the activity of nifurtimox in
zebrafish melanocytes (Figure 3C). Although we do not know if886 Chemistry & Biology 19, 883–892, July 27 , 2012 ª2012 ElsevierPKC directly enhances Aldh2b activity or expression in zebra-
fish, these results suggest that PKC activity is important for
5-nitrofuran cytotoxicity within the melanocyte.Ltd All rights reserved
Figure 4. Cross-Species Conservation of 5-Nitrofuran-ALDH2 Interaction in Yeast
(A) Yeast cultures were treated with NFN1 (red) or NFN1.1 (blue). OD values were normalized against DMSO-treated controls. The mean of two experiments with
three replicates is shown; error bars represent the SE.
(B) Daidzin-NFN1 drug interaction was assessed by combination matrix assays in 96 well plates. Cultures were treated with NFN1 (red) or with daidzin in the
absence (blue) or presence (black) of 50 mM NFN1. The average normalized growth of three experiments is shown; error bars represent the SE.
(C) Normalized growth in the presence of NFN1 was determined for wild-type (blue) and the Dald6 strain (red). Data points are the mean of four replicates; error
bars represent the SE.
(D) NFN1 dose response curves for Dald2Dald3 (red) and the Dald2Dald3Dald6 (black) strains, as well as wild-type control (blue), were generated and normalized
against DMSO-treated controls. The average of three replicates is shown; error bars represent the SE.
(E) Control (n = 24) or aldh2b splice-site morphants (n = 62) at 3 dpf without NFN1 treatment (left) or with 0.8 mMNFN1 treatment (right). Embryos were scored as
class I (strong) or class II (mild) sensitivity to NFN1 (bar graph). aldh2bmorphant embryos were less sensitive to NFN1 treatment compared to control morphants
(p = 0.007; 95% CI [0.139, 0.528]; Fisher’s exact test).
See also Figure S4.
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in Zebrafish Melanocytes
We wanted to understand why zebrafish melanocytes were
sensitive to 5-nitrofuran treatment, when this is not a feature of
5-nitrofuran toxicity in patients. Unlike human melanocytes,
zebrafish melanocytes respond to environmental conditions by
concentrating or dispersing their melanosomes in light or dark
conditions, respectively (Logan et al., 2006). This effect is termed
background adaptation and is a dopaminergic response (Logan
et al., 2006). A role of Aldh2 in zebrafish background adaptation
has not been previously identified, but aldh2b is specifically
expressed in developing pigment cells (Thisse et al., 2001),
and ALDH2 is required for dopamine metabolism in mammals
(Chen et al., 2010). We tested the effects of ALDH2 inhibition
on background adapation in zebrafish and found that daidzin
treatment blocked dispersal of melanin in zebrafish melanocytes
in the dark (Figure 3D). These observations suggest that Aldh2
activity is required for regulation of zebrafish background adap-
tation, and they may explain the sensitivity of zebrafish melano-
cytes to 5-nitrofurans.
Multispecies Conservation of the 5-Nitrofuran-ALDH
Interaction
Chemical-genetic and chemical-chemical interactions identified
in yeast are often conserved in multicellular species including
zebrafish and mammals (Ishizaki et al., 2010). Budding yeast
have five ALDH genes (ALD2–6) that all share 42%–48% simi-
larity with human ALDH 1/2 (Figure S2). Yeast also have two
fungal-specific nitroreductase-like proteins, but these share little
similarity with the nitroreductases that are known to reduce nitro-
furans (de Oliveira et al., 2007). To establish that 5-nitrofuransChemistry & Biology 19,also showed activity in yeast, liquid cultures were treated with
increasing concentrations of NFN1 (Figure 4A). Yeast were highly
sensitive to NFN1, which inhibited growth even at submicromo-
lar concentrations. In contrast, treatment with the control furan
compound, NFN1.1, had no effect on yeast growth, even at
100 mM. These data indicate that the toxicity of 5-nitrofurans in
yeast is dependent on the 5-NO2 moiety. To test whether
NFN1 toxicity was dependent on ALDH activity, we tested
drug combinations in yeast cultures. Increasing concentrations
of daidzin rescued the effects of 50 mM NFN1 on the yeast
growth rate in a dose-dependent fashion, whereas daidzin alone
had no effect on growth (Figure 4B).
Mutations that render yeast resistant to a specific compound
can provide direct links to the target pathway (Ishizaki et al.,
2010). We determined whether yeast strains bearing deletions
in each of the ALD genes (orthologs of human and zebrafish
ALDH1/2) were resistant to 5-nitrofuran treatment. The ald2D,
ald3D, ald4D, and ald5D deletion strains each exhibited the
same sensitivity to NFN1 as wild-type (data not shown). In con-
trast, an ald6D strain was significantly less sensitive to NFN1
treatment, as was an ald2Dald3D double-deletion strain (Figures
4C and 4D). These effects of different aldmutations appeared to
be additive, as a triple ald2Dald3Dald6D deletion strain was
almost completely resistant to 50mMNFN1 treatment (Figure 4D).
Once activated, 5-nitrofurans cause DNA damage, and consis-
tent with this observation, we find that chemical-genetic profiles
in yeast indicate that disruption of DNA damage repair pathways
causes hypersensitivity to 5-nitrofurans (Figure S4).
To further validate the genetic dependence of 5-nitrofuran
bioactivity on Aldh2, we used morpholino oligonucleotides
(MOs) to knockdown aldh2b in zebrafish. Single-cell embryos883–892, July 27 , 2012 ª2012 Elsevier Ltd All rights reserved 887
Figure 5. 5-Nitrofurans Bind and Are Substrates for Human ALDH2 In Vitro
(A) Binding of purified human ALDH2 by 5-nitrofuran probe (Pr-NFN), a furan control probe (Pr-FN), or streptavidin beads alone (No Probe). Arrow indicates
ALDH2 protein, ALDH2 input lane (0.5 mg).
(B) Schematic overview of chemical reaction used to monitor recombinant human ALDH2 activity and experimental design. In experiment C (red arrow), ALDH2
was incubated with 1% DMSO, NFN1, and NFN1.1 or Nifurtimox for 10 min., and then ALDH2 activity was assessed. In experiment D (red + blue arrows), ALDH2
was incubated with 1% DMSO, NFN1, or Nifurtimox for 10 min., incubated with 0.5 mM TCEP or buffer alone for a further 15 min., and then ALDH2 activity was
assessed.
(C) Bar graph of spectrophotometric analysis of the rate of production of NADH (monitored at 341 nm) by ALDH2 (expressed as a percentage of DMSO control
treatment) with DMSO, NFN1, NFN1.1, and Nifurtimox.
(D) Bar graph of spectrophotometric analysis of the rate of production of NADHby ALDH2 after combined treatment of DMSO, NFN1, and Nifurtimoxwith TCEP or
buffer. Enzyme buffer = 50 mM sodium phosphate (pH 7.4). Error bars are SD; experiments were repeated in triplicate.
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were treated with NFN1. PCR analysis of the splice-site MO indi-
cated that aldh2b morphants had reduced levels of correctly
spliced aldh2b transcript in addition to a misspliced transcript,
indicating that the aldh2b morphants are hypomorphic for
aldh2b (Figure S4). We consistently found that the splice-site-
blocking aldh2b MO conferred partial resistance to a low treat-
ment dose (0.8 mM) of NFN1 melanocytotoxicity (Figure 4E). An
aldh2b-translation-block MO also conferred partial resistance
to a short NFN1 treatment (Figure S4). We conclude that there
is a genetic dependence on Aldh2b for 5-nitrofuran activation
in zebrafish, in line with genetic studies in yeast.
5-Nitrofurans Are Substrates for Human ALDH2
There are 19 ALDH enzymes in humans, each with specific
targets and additional activities (Marchitti et al., 2008). To deter-
mine whether the 5-nitrofuran-ALDH2 interaction is conserved in
humans we asked whether human ALDH2 could bind 5-nitrofu-
rans directly. Purified human ALDH2 was added to the 5-nitro-
furan probe (Pr-NFN), a furan control probe (Pr-FN), or streptavi-
din beads alone. In an analogous manner to the experiments
using zebrafish extracts, human ALDH2 binding was strongly
enriched in association with the 5-nitrofuran, while the control
furan and the streptavidin beads alone did not bind ALDH2
(Figure 5A).
Given our results with daidzin in yeast and zebrafish, we
proposed that NFN1 was probably a substrate of ALDH
enzymes. ALDH2 enzymes have reducing potential as well as888 Chemistry & Biology 19, 883–892, July 27 , 2012 ª2012 Elsevierdehydrogenase activity (Chen et al., 2002; Marchitti et al.,
2008), and it has been shown that in the absence of a reducing
agent, ALDH2 inactivates itself during the bioactivation of sub-
strates such as nitroglycerine (GTN) (Chen et al., 2010; Wenzel
et al., 2007). Consistent with this, we found that in the absence
of a reducing agent, NFN1, but not the no-nitro NFN1.1, inacti-
vated recombinant human ALDH2 in vitro (Figures 5B–5D). Like-
wise, we found that ALDH2 activity was reduced by 39.6%,
77.6%, and 96.5% following 10 min incubation with 5 mM nifurti-
mox, 16.7 mM nifurtimox, and 50 mM nifurtimox, respectively
(Figure 5C). Importantly, as with the zebrafish studies, these
experiments were performed with nifurtimox at concentrations
that are within the range of those recorded in the serum of
nifurtimox-treated patients (Paulos et al., 1989; Saulnier Sholler
et al., 2011). For both NFN1- and nifurtimox-inactivated ALDH2,
the subsequent addition of a reducing agent (TCEP) led to partial
reactivation of the enzyme, in line with literature studies using
the accepted substrate, GTN (Figure 5D). We observe that the
NFN1-ALDH2 interaction is stronger than the nifurtimox-ALDH2
in zebrafish and in our biochemical assay. This raises the
possibility that the mechanism of action of nifurtimox is more
complex than that of NFN1, or that NFN1 may in fact be a more
effective 5-nitrofuran substrate of ALDH2 than nifurtimox.
Daidzin Does Not Affect Nifurtimox Trypanocidal
Activity
In an attempt to develop a clinically testable hypothesis, we
examined the genome sequence of the trypanosomatids toLtd All rights reserved
Figure 6. ALDH2 in Trypanosomes
(A) Schematic of a 5-nitrofuran-daidzin combi-
nation-treatment strategy. ALDH2 can cause
5-nitrofuran bioactivtion in ALDH2-expressing
cells (e.g., zebrafish melanocytes), but not in
trypanosomes because they lack ALDH2 (see also
Figure S2). We propose that cotreatment with an
ALDH2 inhibitor such as daidzin could limit
5-nitrofuran toxicity without interfering with anti-
trypanosome activity.
(B) Viability of Trypanosoma brucei (bloodstream
form) at 37C after 72 hr treatment with increasing concentrations of nifurtimox in the absence or presence of daidzin (100 mM). Experiments were conducted
twice in replicates of four; a representative set of data from one experiment containing four replicates is shown. ED, effective dose.
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Leishmania (Figure S2) (Aslett et al., 2010; Cross, 2005; Lowe
et al., 2008; Marchitti et al., 2008; Sobreira et al., 2011). Given
the absence of an obvious ALDH2 in Trypanosoma we hypothe-
sized that while Aldh2 inhibition would protect the zebrafish
melanocytes and yeast cells from 5-nitrofuran activity, ALDH2
inhibitors might not protect trypanosomes from 5-nitrofuran
sensitivity (Figure 6A). We grew the bloodstream-form T. brucei
(strain 427) in HMI9 media and determined the trypanocidal
activity of nifurtimox in the absence and presence of daidzin.
Trypanosomes were stained with an Alamar Blue vital dye as
an indicator of Trypanosoma survival. We found that nifurtimox
was equally effective in the absence (ED50 = 2.12 ± 0.17 mM;
slope 1.00) and presence (ED50 = 2.18 ± 0.10 mM; slope 0.98)
of daidzin (Figure 6B). The trypanocidal effect of nifurtimox
against bloodstream T. brucei obtained in these assays was
comparable to previously observed effects (Priotto et al., 2009;
Sokolova et al., 2010). Daidzin treatment alone showed no trypa-
nocidal effect up to 100 mM (data not shown). We conclude that
daidzin does not interfere with 5-nitrofuran trypanocidal activity,
consistent with a lack of an ALDH2 in trypanosomes.
DISCUSSION
We have used a multispecies, chemical-biology approach to
identify 5-nitrofurans as substrates for ALDH2. We have identi-
fied a series of 5-nitrofuran compounds by phenotypic screening
in zebrafish and have shown that 5-nitrofuran-specific melano-
cytotoxicity in vivo is mediated at least in part by Aldh2 (Figures
1 and 3). Zebrafish gene products are usually conserved in
humans and are often sensitive to clinically active drugs at phys-
iological concentrations (Zon and Peterson, 2005). As shown
here, phenotypic chemical screens in zebrafish are effective
because (1) the rapid and cell-type-specific toxicity of 5-nitrofu-
rans can be visualized in real time (Movie S1), (2) the whole
animal is amenable to pharmacological studies (Figures 1A and
1B), and (3) initial structure activity relationships can be deter-
mined to enable the design of biologically relevant probes for
affinity purification (Figure 2; Table 1).
Despite the benefits of phenotypic screens in zebrafish, target
identification remains a challenge in chemical biology (Laggner
et al., 2012; Taylor et al., 2010; Zon and Peterson, 2005). Here,
we use parallel approaches to enable identification of an impor-
tant target of 5-nitrofurans. First, we used affinity chromatog-
raphy to identify Aldh2 as a 5-nitrofuran binding partner and
confirmed the dependence on the 5-NO2 functional group usingChemistry & Biology 19,an inactive furan probe (Figure 2). Second, we used computa-
tional modeling to predict that the ALDH2 inhibitor daidzin would
be active in zebrafish (Figure 3A), and used two chemically
distinct ALDH2 inhibitors (daidzin and DSF) to confirm the bio-
logical relevance of the 5-nitrofuran-Aldh2 interaction in vivo
(Figures 3B and 3C). Third, we showed cross-species conserva-
tion of the drug-drug interactions in the evolutionarily distant
budding yeast system (Figures 4A and 4B). Fourth, we used
genetic mutants in yeast and gene knockdowns in zebrafish to
validate a genetic dependence on ALDH activity for 5-nitrofuran
activity in vivo (Figures 4C–E). Fifth, we showed that the 5-nitro-
furan-ALDH2 interaction is maintained with human ALDH2 (Fig-
ure 5A). Finally, using a literature-precedent method, we showed
that 5-nitrofurans are direct substrates of human ALDH2 (Figures
5B–5D).
We find that zebrafishmelanocytes are sensitive to the 5-nitro-
furans because unlike human melanocytes, zebrafish melano-
cytes use ALDH2 to elicit a melanocyte background adaptation
response (camouflage; Figure 3D). While additional host
enzymes, possibly including other ALDHs, may bioactivate
5-nitrofurans in patients, we speculate that, in line with our
studies in zebrafish and yeast, daidzin may protect cells that
specifically express ALDH2, such as the liver and dopaminergic
neuronal cells (Figure 6A). Although 500million individuals world-
wide have an ALDH2-inactive variant (Druesne-Pecollo et al.,
2009), it is unknown whether these genetic variants contribute
to the variability of 5-nitrofuran-associated side effects; our
chemical-genetic data in yeast and zebrafish (Figure 4) suggest
that this hypothesis could be examined in the clinic. 5-Nitrofu-
rans have also recently become anticancer agents, and nifurti-
mox is currently in clinical trials for relapsed/refractory pediatric
neuroblastoma and medulloblastoma (Saulnier Sholler et al.,
2011). It is possible that 5-nitrofuran bioactivation by ALDH2
explains the sensitivity of these dopaminergic cancers to nifurti-
mox. We find that human melanoma cells are also sensitive to
nitrofurans, that DNA damage occurs, and that this activity is
dependent on the NO2 functional group present in NFN1 (Fig-
ure S4). Taken together with the hypersensitivity of yeast DNA-
damage mutants to NFN1, these results suggest that once acti-
vated, the cytotoxic effects of 5-nitrofurans arise through a
similar DNA-damage-dependent mechanism across species,
although it is unclear at this time whether NTR- and ALDH2-
mediated activation of 5-nitrofurans leads to exactly the same
toxic intermediates.
We argue that NFN1, but not the no-nitro NFN1.1, is a
substrate for recombinant human ALDH2 in vitro (Figure 5).883–892, July 27 , 2012 ª2012 Elsevier Ltd All rights reserved 889
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tion of nitroglycerin (Chen et al., 2010; Wenzel et al., 2007),
thereby raising the interesting question of how 5-nitrofurans
are bioactivated by ALDH2. ALDH2 enzymes have reducing
potential as well as dehydrogenase activity (Chen et al., 2002;
Marchitti et al., 2008), and we envision that ALDH2 may reduce
the nitro group of 5-nitrofurans, potentially generating nitroso-,
hydroxylamine, and/or amine intermediates with concomitant
oxidation of the enzyme. Interestingly, dithiothreitol (DTT) can
react with 5-nitrofurans, leading to oxidation of DTT to the corre-
sponding disulfide (L.Z. and N.W., unpublished data). As DTT
contains two thiols in close proximity, in an analogous manner
to the active site of ALDH2, we suggest that the reactions of
5-nitrofurans with ALDH2 and DTT may be linked by a common
mechanism.
5-Nitrofurans are important therapeutic agents, yet many
patients suffer from unacceptable drug-induced toxic side
effects. One approach to solving this problem is to identify new
antitrypanosome drug targets, such as the recently identified
N-myristoyltransferase inhibitors (Frearson et al., 2010) that
have been validated in mouse trypanosomiasis models. Based
on our studies in model systems and in vitro, we propose
a complementary approach that involves targeting and mini-
mizing the toxic side effects of current therapies, thereby allow-
ing more patients to benefit from approved treatment regimes
that are already available (Figure 6A). If the 5-nitrofuran-ALDH2
interaction is conserved in patients, then combination therapy
to treat 5-nitrofuran toxic side effects may be testable, because
(1) ALDH2 is a targetable enzyme; (2) the ALDH2 inhibitors daid-
zin and DSF are both currently available at low cost and show
activity in humans with limited toxicity; and (3) our analysis indi-
cates that T. brucei and T. cruzi do not have a close ALDH2
homolog (Figure S2), nor is T. brucei protected from nifurtimox
by daidzin (Figure 6B). Our findings provide impetus for address-
ing the role of ALDH2 in 5-nitrofuran activation in the preclinical
and clinical setting.
SIGNIFICANCE
Discovering how drugs work in vivo and identifying unin-
tended drug targets is a fundamental challenge in chemical
biology. Nifurtimox is one of only two drugs used to treat
Chagas disease, caused by Trypanosoma cruzi infection,
which is estimated to affect over 10 million people per year
and kills between 15,000 and 50,000 annually. Like other
5-nitrofurans, nifurtimox is a prodrug that is activated by
parasite-specific nitroreductases to a toxic form. Despite
the absence of nitroreductases in humans, 5-nitrofurans
cause significant clinical off-target toxic side effects that
interfere with patients’ ability to complete the treatment
course. There has been no significant improvement in
trypanosome disease treatment for 40 years, and there is
currently no treatment strategy in patients to reduce the
burden of these toxic side effects of existing drugs.
Here, we use model organism chemical genetics to
explore the basis for this toxicity. We use the zebrafish
model (1) to identify toxic effects of 5-nitrofuran compounds;
(2) as a platform for structure-activity relationships and
target identification; and (3) to show that the toxicity of890 Chemistry & Biology 19, 883–892, July 27 , 2012 ª2012 Elsevier5-nitrofurans in zebrafish can be prevented by cotreatment
with aldehyde dehydrogenase 2 (ALDH2) inhibitors. We
then show that the ALDH2-5-nitrofuran interaction is
conserved in yeast and with human ALDH2 and argue that
5-nitrofurans are a direct substrate of human ALDH2. We
extend these findings to show that the 5-nitrofuran nifurti-
mox also has Aldh2-dependent activity in zebrafish, and
that it is a direct substrate of human ALDH2. Thus, we
show in model systems that drug treatments combining
ALDH2 inhibitors with 5-nitrofurans block the 5-nitrofuran
unintended biological activity, and we propose that similar
treatments based on a readily available combination of inex-
pensive approved drugs may prevent some of the clinical
side effects caused by 5-nitrofurans.
EXPERIMENTAL PROCEDURES
Zebrafish Small-Molecule Screens and Treatments
All zebrafish work was done in accordance with United Kingdom Home Office
Animals (Scientific Procedures) Act (1986) and approved by the University of
Edinburgh Ethical Review Committee. The chemical library was a collection
of 1576 Maybridge compounds (Ishizaki et al., 2010). Two 4 hpf embryos
were arrayed in 96 well plates containing 10 mM of compound in 1% DMSO
in 300 ml of E3 embryo medium. Embryos were assessed and imaged for
phenotypic changes at 28, 36, 48, and 56 hpf. For the screening of The
Screen-Well Kinase Inhibitor Library (Enzo Life Sciences), five embryos
(24 hpf) were placed into each well of a 24 well plate (Corning) containing
20 mM NFN1 (BTB05727, Maybridge Screening compounds) and 5, 10, or
20 mM of a corresponding compound (total volume 1 ml per well). For cotreat-
ment experiments, five 36–48 hpf embryos were arrayed in 24 well plates in
600 ml to 1 ml of E3 embryo medium and pretreated with ALDH or PKC inhib-
itors (1–7 hr), and then treated with 0.5–5 mM NFN1 or 50 mM nifurtimox.
Affinity Purification and Coimmunoprecipitation
with 5-Nitrofuran Beads
Lysate was generated from approximately 900 3 dpf zebrafish in 300 ml of
RIPA buffer (2 M Tris pH 7.5, 5 M NaCl, 1% NP40, Na-deoxycholate, 10%
SDS, 0.5 M NaF, 1 M b-glycosyl phosphate and protease-inhibitor cocktail
tablet [Roche]), centrifuged at 4C (25 min), transferred to a new tube, and
kept on ice. Protein capture was performed using a pull-down biotinylated
protein:protein interaction kit (Pierce) using the biotinylated chemical probe
(5 ml 10 mg/ml DMSO solution), and bead complexes were washed with
0.1 M NaCl TBS buffer four times to reduce nonspecific binding. Beads
were boiled in 33 Laemmli buffer with DTT for 5 min and run on 10% SDS-
PAGE gel for electrophoresis. Captured proteins were visualized with a
Silverquest silver-staining kit and/or Colloidal blue-staining kit (Invitrogen).
Themass spectroscopy was analyzed in the University of Dundee FingerPrints
Proteomics Facility. For western blotting, protein was detected using rabbit
anti-zebrafish Aldh2 (1:1000) and goat anti-rabbit antibody (1.5:5000;
Calbiochem).
In Vitro Binding Assay
ALDH2 human recombinant protein (ProSpec) was added to 4 ml 10 mg/ml of
chemical probe with 100 ml TBS buffer and incubated at room temperature for
1 hr. Streptavidin bead suspension (50 ml) was added to the mixture (room
temperature; 1 hr), the supernatant was removed, and beads were washed
with 4 3 0.1 M NaCl TBS buffer, boiled in 33 Laemmli buffer with DTT for
5 min, and run on 10% SDS-PAGE gel for electrophoresis. The bands were
detected by silver staining (Invitrogen).
Molecular Modeling
Using methods analogous to those used previously (Medda et al., 2009), the
zebrafish Aldh2b homology model was generated using the Swiss model
server using bovine ALDH2 (PDB code 2AG8). The daidzin structure was
generated using the PRODRG server. The docking studies were performedLtd All rights reserved
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Pymol.
Yeast Growth Assays
Overnight S. cerevisiae BY4741 cultures in SC media were diluted
(OD600 0.025) and dispensed into 96 well Corning Costar assay plates. Quan-
titative growth curves were generated in Tecan Sunrise plate readers at 30C
564 rpm with automated absorbance reads every 15 min. Growth-curve data
were used to determine when control cultures reached late log phase, and OD
values of the entire plate at that time point were used to calculate normalized
growth values. Data were analyzed with custom R scripts to generate plots.
For the deletion-strain growth curves, normalization was performed against
control wells for each strain.
Trypanocidal Studies
The trypanocidal activity of nifurtimox in the absence and presence of daidzin
(100 mM) against Trypanosoma brucei bloodstream form (strain 427) were
cultured at 37C in HMI9 medium supplemented with 2.5 mg ml–1 G418, and
viability was determined using the Alamar Blue test, as described previously
(Mikus and Steverding, 2000). The data were fitted using GraFit software to
obtain ED50 ± SD and slope factors.
Supplemental Experimental Procedures
The synthesis of all theNFNs andNFN-based affinity probes is described in the
Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, Supplemental
Experimental Procedures, and one movie and can be found with this article
online at http://dx.doi.org/10.1016/j.chembiol.2012.05.017.
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